Morningstar

Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting

Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting Circle Pharma, a clinical-stage biopharmaceutical company ...
VentureBeat

Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors

Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) ...
VentureBeat

Circle Pharma Announces Preclinical Data Poster Presentation of CID-078, a First-and-Only-in-Class Cyclin A/B RxL Inhibitor at the 2024 World Conference on Lung Cancer

Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycle therapies, today announced that it presented a digital poster at the 2024 ...
Business Wire

Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
Business Wire

Circle Pharma Presents Promising Preclinical Data on First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor CID-078 at the San Antonio Breast Cancer Symposium 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
Morningstar

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer ...

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on ...